Celcuity (CELC) slides 6% as traders reset expectations into July 17 FDA deadline
Celcuity shares are sliding as investors reposition after the company’s recent Q4/FY2025 update highlighted heavy spending ahead of a key FDA decision. The next major catalyst remains the July 17, 2026 PDUFA goal date for gedatolisib, keeping the stock sensitive to sentiment swings.
1. What’s moving the stock
Celcuity (CELC) is down about 6% in the latest session as the market digests the company’s most recent operating and regulatory update and traders de-risk into the next binary catalyst. The stock has been highly momentum-driven, and the absence of a fresh positive catalyst today is pressuring shares after recent strength into early April.
2. The key catalyst: FDA timeline for gedatolisib
Celcuity’s lead asset, gedatolisib, is under Priority Review at the FDA for HR+/HER2-/PIK3CA wild-type advanced breast cancer, with a PDUFA goal date of July 17, 2026. With that decision still months away, CELC can trade sharply on shifting expectations around approval probability, launch readiness, and valuation sensitivity to timelines.
3. Spending ramp and headline financial context
In its March 25, 2026 corporate update alongside full-year 2025 results, Celcuity reported a wider GAAP net loss for 2025 and described a material increase in operating expense levels as it builds commercial capabilities and continues development programs. The company also disclosed year-end 2025 cash, cash equivalents and short-term investments of $441.5 million, which it said it expects to finance operations through 2027—data points that can still trigger profit-taking when the market rotates away from high-beta biotech.
4. What investors will watch next
Near term, investors are focused on two dates: (1) topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study expected in Q2 2026, and (2) the July 17, 2026 FDA action date for the current NDA. Any perceived pushout, incremental safety scrutiny, or softer read-through into commercialization execution can drive outsized day-to-day moves even without new company headlines.